FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

								.,											
1. Name and Address of Reporting Person* Hasnain Faheem						2. Issuer Name and Ticker or Trading Symbol BIOGEN IDEC INC. [BIIB]								Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last) (First) (Middle) 14 CAMBRIDGE CENTER						3. Date of Earliest Transaction (Month/Day/Year) 02/06/2008								X Officer (give title Other (spec below) EVP, Oncology/Rheumatology SBU					
(Street) CAMBR (City)		[A tate)	4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)							Line	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person							
		Tab	le I - No	n-Deriv	vative	e Sec	curiti	ies Ac	guired.	Dis	posed c	of, or Be	neficial	ly Owned					
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da				action	tion 2A. Deemed Execution Date,		med on Date,	3. Transaction Code (Instr.		4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4 5)			5. Amour Securitie Beneficia Owned F	nt of es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
								Code	v	Amount	(A) or (D)	Price	Transact	Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)		
Common Stock 02/0					5/2008	2008		М		5,467	A	\$0.00	31,451	31,451.6236(1)		D			
Common Stock 02/06				5/2008	2008		F		2,017	D	\$60.5	29,434.6236			D				
		1	able II -								osed of converti			Owned					
Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year)	n Date,	4. Transa Code (8)		on of I		6. Date Exercisal Expiration Date (Month/Day/Year		Amount of		f g Security	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	Ownersh Form: y Direct (D or Indirec (I) (Instr.	Ownership Form:	Beneficial Ownership t (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title	Amount or Number of Shares						
Restricted	\$0.00	02/06/2008			M			5,467	02/06/200	08	02/06/2008	Common	5,467	\$0.00	5,466		D		

Explanation of Responses:

1. Includes 66.5262 shares acquired under the Biogen Idec Inc. employee stock purchase plan on 12/31/2007.

Remarks:

Stock Unit

Robert A. Licht, Attorney in Fact for Faheem Hasnain

Stock

02/07/2008

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{*} If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).